FDA okays expanded PAD study
This article was originally published in The Gray Sheet
Executive SummaryCardiovascular Systems is enrolling patients for a clinical trial evaluating the use of its Orbital Atherectomy System (OAS)in the treatment of peripheral arterial disease. The firm announced FDA go-ahead for the OASIS trial July 19. The catheter-based device removes plaque from peripheral arteries via a diamond-coated crown that creates a lumen twice its size, the firm says. The company estimates more than 12 mil. Americans suffer from PAD, which left untreated could lead to leg amputation...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.